Monaco Asset Management SAM Takes Position in QuidelOrtho Corporation $QDEL

Monaco Asset Management SAM bought a new position in QuidelOrtho Corporation (NASDAQ:QDEL) in the second quarter, HoldingsChannel reports. The firm bought 65,000 shares of the company’s stock, valued at approximately $1,138,000. QuidelOrtho accounts for 0.1% of Monaco Asset Management SAM’s holdings, making the stock its 26th largest holding.

Several other large investors have also recently modified their holdings of QDEL. Invesco Ltd. lifted its position in QuidelOrtho by 87.0% in the third quarter. Invesco Ltd. now owns 2,906,763 shares of the company’s stock worth $85,604,000 after buying an additional 1,352,503 shares during the last quarter. Newtyn Management LLC lifted its holdings in shares of QuidelOrtho by 58.3% in the 3rd quarter. Newtyn Management LLC now owns 2,700,000 shares of the company’s stock worth $79,515,000 after acquiring an additional 994,332 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of QuidelOrtho by 101.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,755,401 shares of the company’s stock worth $50,134,000 after purchasing an additional 883,077 shares during the period. T. Rowe Price Investment Management Inc. boosted its stake in shares of QuidelOrtho by 7.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 11,832,098 shares of the company’s stock worth $337,925,000 after purchasing an additional 819,908 shares during the period. Finally, Paradigm Capital Management Inc. NY grew its holdings in QuidelOrtho by 84.1% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,525,900 shares of the company’s stock valued at $25,071,000 after purchasing an additional 697,010 shares during the last quarter. Institutional investors own 99.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on QDEL. UBS Group reissued a “neutral” rating and issued a $12.00 price objective on shares of QuidelOrtho in a research note on Thursday, May 7th. Wall Street Zen upgraded QuidelOrtho from a “sell” rating to a “hold” rating in a report on Sunday, June 28th. Citigroup lifted their target price on QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of QuidelOrtho in a report on Friday, July 17th. Finally, Jefferies Financial Group restated a “hold” rating on shares of QuidelOrtho in a research note on Monday, June 29th. Three analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $13.62.

QuidelOrtho Price Performance

QDEL opened at $14.30 on Monday. The company has a market capitalization of $980.55 million, a price-to-earnings ratio of -0.93 and a beta of 0.68. The company has a current ratio of 1.39, a quick ratio of 0.76 and a debt-to-equity ratio of 1.43. QuidelOrtho Corporation has a 12-month low of $9.92 and a 12-month high of $35.58. The business’s fifty day simple moving average is $15.80 and its 200-day simple moving average is $16.89.

QuidelOrtho (NASDAQ:QDEL) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.18. QuidelOrtho had a positive return on equity of 4.88% and a negative net margin of 39.20%.The firm had revenue of $630.90 million during the quarter, compared to the consensus estimate of $618.72 million. During the same period in the previous year, the company posted $0.12 earnings per share. The firm’s quarterly revenue was up 2.8% on a year-over-year basis. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. On average, equities research analysts anticipate that QuidelOrtho Corporation will post 0.75 earnings per share for the current fiscal year.

QuidelOrtho Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.